We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current GNMSF market cap is 13.62B. The company's latest EPS is DKK 66.2490 and P/E is 3.05.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Total Revenue | 5.37B | 10.11B | 8.48B | 14.6B | 16.47B |
| Operating Income | 2.64B | 6.31B | 3.02B | 6.36B | 5.32B |
| Net Income | 2.17B | 4.76B | 3.01B | 5.52B | 4.35B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Total Assets | 15.14B | 21.14B | 24.63B | 30.28B | 35.29B |
| Total Liabilities | 1.1B | 2.02B | 2.43B | 2.84B | 3.68B |
| Total Equity | 14.05B | 19.12B | 22.2B | 27.44B | 31.61B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Operating | 1.33B | 6.43B | 2.23B | 3.91B | 7.38B |
| Investing | -1.98B | -2.35B | -961M | -2.76B | -1.28B |
| Financing | 3.66B | 71M | -420M | -789M | -606M |
| Market Cap | 13.62B |
| Price to Earnings Ratio | 3.05 |
| Price to Sales Ratio | 0.81 |
| Price to Cash Ratio | 0.89 |
| Price to Book Ratio | 0.42 |
| Dividend Yield | - |
| Shares Outstanding | 65.69M |
| Average Volume (1 week) | 1.64k |
| Average Volume (1 Month) | 4.79k |
| 52 Week Change | -33.80% |
| 52 Week High | 334.328 |
| 52 Week Low | 192.20 |
| Spread (Intraday) | 42.58 (18.6%) |
| Company Name | Genmab A S (PK) |
| Address |
kalvebod brygge 43 copenhagen 1260 |
| Website | https://www.genmab.com |
| Industry | biogenetic (human) (H4) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
